RegWatch by RegulatorWatch.com

Brent Stafford

Incisive coverage of the issues important to vaping. Plus critical debate over the issues and impacts of regulation in both Canada and the U.S.

  1. Sep 10

    YES, IT IS A WAR | Health Economist Rebukes FDA’s Campaign Against Vaping | RegWatch

    For nearly a decade, the U.S. vaping community has called the FDA’s campaign against nicotine vapes a war on vaping. Beginning with the deeming rule, the agency’s aggressive action against Juul, the so-called teen-vaping epidemic, the “Real Cost” campaign, the denial of millions of PMTA applications, and FDA’s steadfast refusal to counter misinformation and set the record straight on the relative risks and benefits of vaping versus smoking—it certainly feels like a war. But is it? In this episode of RegWatch, Dr. Raymond March, Director of FDAReview.org and Research Fellow at the Independent Institute, says: “Oh, absolutely. It might be the biggest war the FDA has waged.” March argues FDA regulation has protected Big Tobacco, enabled selective enforcement, and distorted public understanding of relative risk. Rather than protecting public health, he says the agency’s approach has been self-serving, politically malleable, and extraordinarily destructive. Could the FDA be winning its war on vaping, or is the war finally nearing its end? Find out. Only on RegWatch by RegulatorWatch.com. Released: September 9, 2026 Produced by: Brent Stafford https://youtu.be/sv4To6UxRcE This episode is supported by DEMAND VAPE. CELEBRATE WITH US | RegWatch 10th Anniversary Fundraising Campaign GoFundMe: https://www.gofundme.com/f/regwatch-10th-anniversary-fundraiser #RegWatch #VapeNews

  2. Jul 25

    STRIKING CONTRAST | Science, Politics & the Battle Over Nicotine Pouches | RegWatch

    The deadliest nicotine products in America remain the easiest to buy, while lower-risk alternatives face the toughest fight for regulatory approval and political acceptance. It’s a striking contrast. Despite recent progress at the FDA, nicotine pouches remain caught in vaping’s regulatory and political wake. They are inheriting the regulatory paralysis, legislative backlash, and moral panic created by the battle over vaping. In Part 1 of this three-part RegWatch special series, Laura Leigh Oyler, Vice President of Regulatory Affairs for Haypp Group, draws on 17 years in tobacco harm reduction to explain the stakes for adult consumers, responsible retailers, and public health. Oyler breaks down the FDA’s years-long PMTA delays, its failure to provide pouch-specific guidance, the growth of illicit and counterfeit products, and the landmark modified-risk authorization permitting the claim that using ZYN instead of cigarettes reduces the risk of serious disease. She also warns that tobacco control is already branding nicotine pouches as “the next Juul,” driving fear and misinformation into state legislation. With more than 1,200 combustible tobacco products authorized since 2020 and millions of Americans still smoking, why do the lowest-risk alternatives continue to face the greatest resistance? Find out. Only on RegWatch by RegulatorWatch.com. Only on RegWatch by RegulatorWatch.com. Released: July 25, 2026 Produced by: Brent Stafford https://youtu.be/3M-05qpX70w CELEBRATE WITH US | RegWatch 10th Anniversary Fundraising Campaign GoFundMe: https://www.gofundme.com/f/regwatch-10th-anniversary-fundraiser #RegWatch #VapeNews

About

Incisive coverage of the issues important to vaping. Plus critical debate over the issues and impacts of regulation in both Canada and the U.S.